Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma

Chinese Journal of Pathology

Volumn 38, Issue 1, 2009, Pages 35-41

  Yu, Bao Hua ^a   Zhou, Xiao Yan ^a   Xiao, Xiu Ying ^a   Yan, Shi Yan ^a   Qin, Tao ^a   Shi, Da Ren ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

1 phosphatidylinositol 3 kinase; Lymphoma, large cell, diffuse; Protein kinases; Reverse transcriptase polymerase chain reaction

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PARAFFIN; PROTEIN BCL 6; PROTEIN KINASE B;

ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-6; RNA, MESSENGER; SEX FACTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 59049091930     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2009.01.009     Document Type: Article

References (33)

1. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol, 2005, 23(26) : 6351-6357.
2. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002, 2(7) : 489-501.
3. Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mT0R/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol, 2004, 287(2) : C281-291.
4. Gao N, Zhang Z, Jiang BH, et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun, 2003, 310(4) : 1124-1132.
5. Zhou X, Tan M, Stone V, et al. Activation of the Akt/mTOR/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res, 2004, 10(20) : 6779-6788.
6. Smith PG, Wang F, Wilkinson KN, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood, 2005, 105(1) : 308-316.
7. Chinese source
8. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood, 2006, 108(13) : 4178-4186.
9. Yu BH, Zhou XY, Zhang TC, et al. Mutations of PIK3CA Gene in Diffuse Large B Cell Lymphoma. Diagn Mol Pathol, 17(3) : 159-165.
10. David O, Jett J, LeBeau H, et al. Phospho-Akt Overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res, 2004, 10(20) : 6865-6871.
11. Stal O, Perez-Tenorio G, Akerberg L, et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res, 2003, 5(2) : R37-R44.
12. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103(1) : 275-282.
13. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Aky signaling. Oncogene, 2003, 22(7) : 974-982.
14. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role if phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res, 2001, 61(5) : 2194-2199.
15. Granville CA, Memmott RM, Gills JJ, et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-Kinase/Akt/Mammalian target of rapamycin pathway. Clin Cancer Res, 2006, 12(3) : 679-689.
16. Vignot S, Faivre S, Aguirre D, et al. MTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol, 2005, 16(4) : 525-537.
17. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin section of normal lymphoid tissue ans B-cell lymphomas. Am J Surg Pathol, 2000, 23(6) : 846-852.
18. Tang TT, Dowbenko D, Jackson A, et al. The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem, 2002, 277(16) : 14255-14265.
19. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403(6769) : 503-511.
20. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Engl J Med, 2002, 346(25) : 1937-1947.
21. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood, 2005, 106(5) : 1770-1777.
22. Lu X, Nechushtan H, Ding F, et al. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood, 2005, 105(7) : 2924-2932.
23. Muris JF, Cillessen SG, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood, 2005, 105(7) : 2916-2923.
24. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med, 2001, 194 (12) : 1861-1874.
25. Iqbal J, Neppalli VT, Wright G, et al. Bcl-2 expression is a prognostic marker for the ABC-like type of DLBCL. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24 (6) : 961-968.
26. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer, 2002, 86(4) : 540-545.
27. Opel D, Poremba C, Simon T, et al. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res, 2007, 67(2) : 735-745.
28. Komblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood, 2006, 108(7) : 2358-2365.
29. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res, 2004, 10(19) : 6572-6578.
30. Mawrin C, Sasse T, Kirches E, et al. Different activation of mitogenactivated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res, 2005, 11(11) : 4074-4082.
31. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res, 2002, 8(3) : 885-892.
32. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2001, 98(4) : 945-951.
33. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med, 2004, 350(18) : 1828-1837.